Sure! Here’s the translation into American English:
<div itemprop="text">
<p>Theriva™ Biologics, a company focused on developing innovative cancer therapies, has announced the success of its Phase 2b clinical trial with VCN-01, an oncolytic adenovirus aimed at treating metastatic pancreatic ductal adenocarcinoma (mPDAC). This study, called VIRAGE, has met the primary endpoints in terms of efficacy and safety, marking a significant advancement in the fight against this highly aggressive form of cancer.</p>
<p>Theriva's CEO, Steven A. Shallcross, highlighted that patients who received VCN-01 in combination with standard chemotherapy showed a significant improvement in overall survival and duration of response compared to those who only underwent conventional treatment. Shallcross also mentioned that the company is in the process of scaling up manufacturing of the treatment and finalizing the design of a Phase 3 trial, aiming to provide this innovative therapeutic option in the near future.</p>
<p>Recently, Theriva completed a public offering, increasing its liquidity through the first quarter of 2026. The company plans to allocate these funds mainly for research and development, as well as to boost production of VCN-01. In the first quarter of 2025, Theriva reported general and administrative expenses of $1.4 million, which represents a decrease from $1.9 million the previous year, highlighting a focus on operational efficiency.</p>
<p>Data from the VIRAGE trial, which involved patients at centers in the United States and Spain, showed that those who received multiple doses of VCN-01, along with more cycles of chemotherapy, experienced a notable improvement in their survival rate. These results will be presented at a virtual event bringing together oncology experts to discuss their implications.</p>
<p>With this promising news, Theriva Biologics is poised to become a key player in the battle against pancreatic cancer, a disease frequently diagnosed at advanced stages and with a survival rate that remains alarmingly low. The company is determined to continue innovating and developing treatments that can provide new hope to patients affected by this devastating disease.</p>
</div>via: MiMub in Spanish
